亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文


Icotinib hydrochloride is a National Class 1.1 new drug that is independently developed by Betta Pharmaceuticals Co., Ltd. for nearly a decade. It is also China's first small molecule targeted anti-cancer drug. Icotinib is a potent and highly selective oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and it is used for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients carrying EGFR mutations. 
On June 7th, 2011, Icotinib hydrochloride was approved by the National Medical Products Association (NMPA), fulfilling the unmet medical needs in China.
On August 12th, 2011, the market launch of Icotinib hydrochloride was held in the Great Hall of the People in Beijing. It was praised as a groundbreaking scientific and technological achievement in the China healthcare industry.
In 2012, Icotinib hydrochloride was included on Citeline’s “Pharm R&D Annual Review for 2012”, which was the first time a Chinese innovative drug was included on such report.
On August 13th, 2013, the phase III ICOGEN clinical trial results of Icotinib hydrochloride were published on the Lancet Oncology (Shi, Y., et al., The Lancet Oncology 14 (10) p953-961). Professor of the University of Colorado, Dr. David Camidge, commented that Icotinib has opened a new era of anticancer drug research in China, which is a significant milestone in the global oncology research.

1698306007803090.png

In 2012 and 2014, icotinib hydrochloride won the Golden Prize of Chinese Patent Award for its composition of matter and the crystal form patents.
In 2015, icotinib hydrochloride won “First Prize of National Science and Technology Progress Award 2015”.
In 2016, icotinib hydrochloride won “Chinese Industry Award”. In the same year, it was included in the first round of the price negotiation with the Chinese National Health Commission and created a new model for medical insurance negotiation, which reduced the burden of Chinese patients.
In 2017, icotinib hydrochloride was enlisted on the National Reimbursement Drug List (NRDL). On July 19th, the BRAIN clinical study results of icotinib hydrochloride for NSCLC brain metastasis treatment were published in the Lancet Oncology (Jin-Ji, Y., et al., The Lancet Oncology 5 (9) p707-716). It is the first phase III study of EGFR TKI targeting NSCLC patients with brain metastasis, and this treatment is recommended in the clinical guide. On August 23rd, the first-line clinical study of icotinib hydrochloride in NSCLC patients carrying EGFR mutations was published in the Annual of Oncology, which provided clinical support for its use in the first-line setting.
In 2018, icotinib hydrochloride was included on the National Essential Drug List (EDL), giving access to more Chinese patients.
In 2019, icotinib hydrochloride was included on the General Drug Access Catalogue of National Medical Insurance, further reducing the economic burden of NSCLC patients.



1.png

主站蜘蛛池模板: 国产精品亚洲片精品88av | 欧洲精品码一区二区三区 | 欧美 xxxx18性欧美 | 亚洲国产成a人v在线观 | 国产真实乱子伦精品视手机观看 | 在线观看国产精品 | 人妻丰满熟妇 | 欧洲永久精品大片ww网站 | 久久视频在线视频观看2024 | 精品无码一区在线观看 | 欧美在线一区二区 | 国产成人无码av在线播放无广 | 亚洲爆乳无码一区二区三区 | 无码成a∧人片在线播放 | av在线资源入口爱豆传媒md0181 | 久久精品伊人波多野结 | 成人无遮挡裸免费视频在线观看 | 国精产品99永久中国有限公司 | 久久久久中文无码精品 | 久久精品国产亚洲av无码娇色 | 国产成人精品一区二三区在线 | 欧美亚洲精品中文字幕乱码免费 | 亚洲91成人在线观看 | 2024最新精品国自产拍视频 | 18国产精品 | 91久久精品日日躁夜夜躁 | 91久久北条麻妃一区二区三区 | 亚洲欧美日韩中文综合v日本 | 欧美日韩国产亚洲图片成人网 | 久久精品亚洲精品无码白云tv | 一本之道中文字幕久久美香 | 东京热日韩无码高清国产精品 | a级片在线观看免费 | 国产成人91亚洲精品无码观看 | 国产成人av在线免播放观看 | 精品成人免费一区二区 | 亚洲av成人一区二区三区在线观看 | 黑人狂躁日本妞免费视频 | 欧美日韩亚洲一区二区精品 | 久久无码人妻中文国产AV苍井空 | 日本免费三级网站 |